Intriguingly, fingolimod improved outcomes in a proof-of-concept clinical trial of 23 patients with intracerebral hemorrhage at both acute (days) and chronic (months) time points [37], consistent with S1P signaling effects in human stroke. Here, MBTPS1 is linked to Stroke.